Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-14 |
2024-03 |
0 |
-0.2 |
N/A |
N/A |
2024-03-12 |
2023-12 |
0 |
N/A |
N/A |
N/A |
2023-11-14 |
2023-09 |
0 |
-8.41 |
N/A |
N/A |
2023-10-06 |
2023-06 |
0 |
N/A |
N/A |
N/A |
2023-05-15 |
2023-03 |
0 |
-3.6 |
N/A |
N/A |
2023-03-31 |
2022-12 |
0 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-09-21 |
Guggenheim |
Downgrade |
Buy |
Neutral |
2023-09-20 |
Benchmark |
Upgrade |
Speculative Buy |
Speculative Buy |
2023-09-20 |
Guggenheim |
Downgrade |
Buy |
Neutral |
2023-09-20 |
Cantor Fitzgerald |
Downgrade |
Overweight |
Neutral |
2023-08-21 |
Cantor Fitzgerald |
Upgrade |
Overweight |
Overweight |
2023-08-14 |
Cantor Fitzgerald |
Upgrade |
Overweight |
Overweight |
Date |
Name |
Relation |
Quantity |
Description |
2022-05-25 |
DALESANDRO MARGARET PH.D |
Director |
35.00K |
Purchase |
2017-08-30 |
DENNER ALEXANDER J |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Purchase |
2018-08-29 |
DORSEY BRIAN T |
Former |
115.89K |
Conversion of Exercise of derivative security |
2024-02-28 |
GOLEMBIEWSKI MICHAEL JOSEPH |
Chief Financial Officer |
86.87K |
Stock Award(Grant) |
2017-01-04 |
MAIER PAUL V |
Director |
13.85K |
Stock Award(Grant) |
2023-11-30 |
MEHRA RAJ |
Chief Executive Officer |
185.14K |
Purchase |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Gendell, Jeffrey L. |
5.17M |
6.18M |
4.04% |
2023-06-29 |
Vanguard Group Inc |
5.00M |
5.97M |
3.91% |
2023-09-29 |
Wealth Effects LLC |
3.61M |
663.37K |
2.82% |
2023-06-29 |
Blackrock Inc. |
1.68M |
2.01M |
1.31% |
2023-06-29 |
Geode Capital Management, LLC |
1.17M |
1.39M |
0.91% |
2023-06-29 |
Uniplan Investment Counsel, Inc. |
1.12M |
1.34M |
0.88% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
3.36M |
4.01M |
2.62% |
2023-06-29 |
Vanguard Extended Market Index Fund |
1.46M |
1.74M |
1.14% |
2023-09-29 |
AdvisorShares Trust-AdvisorShares Psychedelics ETF |
621.32K |
114.32K |
0.49% |
2023-05-30 |
Fidelity Extended Market Index Fund |
568.07K |
529.04K |
0.44% |
2023-05-30 |
Fidelity Total Market Index Fund |
197.13K |
183.59K |
0.15% |
2023-05-30 |
Fidelity Series Total Market Index Fund |
127.03K |
118.30K |
0.10% |
Split |
Date |
1 : 8 |
2024-05-16 |
1 : 30 |
2023-11-28 |
1 : 30 |
2019-01-24 |
1 : 10 |
2016-10-24 |
0.06667 : 1 |
2010-06-21 |